John Geddes
Corporate Officer/Principal chez CARDIOL THERAPEUTICS INC.
Profil
John A.
Geddes is currently the Vice President-Business Development at Cardiol Therapeutics, Inc. He previously worked as the Director-Business Development at Luminex Corp., the Associate Director-Business Development at Novo Nordisk Canada, Inc., and the VP-Business Development & Marketing at Vasogen, Inc. Mr. Geddes holds an MBA from Richard Ivey School of Business and undergraduate degrees from Queen’s University Belfast and Queen's University.
Postes actifs de John Geddes
| Sociétés | Poste | Début |
|---|---|---|
| CARDIOL THERAPEUTICS INC. | Corporate Officer/Principal | 01/01/2022 |
Anciens postes connus de John Geddes
| Sociétés | Poste | Fin |
|---|---|---|
Novo Nordisk Canada, Inc.
 Novo Nordisk Canada, Inc. Pharmaceuticals: MajorHealth Technology Novo Nordisk Canada, Inc. provides healthcare services. The firm specializes in the areas of coagulation disorders, growth disorders and hormone replacement therapy. The company was founded in 1993 and is headquartered in Mississauga, Canada. | Corporate Officer/Principal | - |
Vasogen, Inc.
 Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | Corporate Officer/Principal | - |
| LUMINEX CORPORATION | Corporate Officer/Principal | - |
Formation de John Geddes
| Queen's University | Undergraduate Degree |
| Richard Ivey School of Business | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| CARDIOL THERAPEUTICS INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Vasogen, Inc.
Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | Health Technology |
Luminex Corp.
 Luminex Corp. Medical SpecialtiesHealth Technology Luminex Corp. develops, manufactures and markets proprietary biological testing technologies and products with applications throughout the life sciences and diagnostics industries. The firm's products are focused on the molecular diagnostic testing market, which includes human genetics, personalized medicine and infectious disease segments. The company was founded by Mark B. Chandler and Van S. Chandler in May 1995 and is headquartered in Austin, TX. | Health Technology |
Novo Nordisk Canada, Inc.
Novo Nordisk Canada, Inc. Pharmaceuticals: MajorHealth Technology Novo Nordisk Canada, Inc. provides healthcare services. The firm specializes in the areas of coagulation disorders, growth disorders and hormone replacement therapy. The company was founded in 1993 and is headquartered in Mississauga, Canada. | Health Technology |
